Stryker Puts $400 Million Into CMR Surgical for a Buyout Option and U.S. Sales Rights, Price Undisclosed

Stryker will invest about $400 million (£300 million) in preferred equity in CMR Surgical, the Cambridge, England maker of the Versius soft-tissue surgical robot, and gets an exclusive option to buy the rest of the company. Stryker announced the alliance on Oct. 12, 2026. Neither the option's price nor its timing was disclosed.

Stryker also becomes the exclusive U.S. sales agent for the Versius portfolio, while CMR keeps leading development and commercialization outside the United States. The investment is subject to regulatory approvals and customary closing conditions, according to Stryker's release.

What Stryker's release does and does not say

The release names two executives. Andy Pierce, group president of Medsurg and Neurotechnology at Stryker, said the company evaluated the segment "carefully for years" and called the deal a "thoughtful and disciplined entry". Massimiliano Colella, chief executive of CMR Surgical, called it "a significant milestone" for CMR. Pierce will join CMR's board.

The release gives no Versius installed base and no procedure count. It does not give the option's exercise price, the rights attached to the preferred equity, or any valuation.

Term	Disclosed?	Detail
Investment size	Yes	About $400 million, preferred equity
Option to buy all remaining equity	Yes, existence only	Price and timing not given
U.S. sales	Yes	Stryker is exclusive sales agent
Board	Yes	Andy Pierce joins
Installed base	No	Not in release or MedTech Dive

Source: Stryker press release, Oct. 12, 2026; MedTech Dive, Oct. 12, 2026.

The number that matters is procedures, not dollars

The number that matters here is not $400 million but what CMR has actually done with its robots. MedTech Dive's Elise Reuter reports that, as of early 2026, CMR had performed more than 45,000 procedures globally, a figure from J.P. Morgan analyst Robbie Marcus. Stifel analyst Rick Wise estimated CMR is roughly second or third in the global robotic installed base, though the article gives no installed-system count.

A crude denominator follows. Spread $400 million over 45,000 procedures and you get about $8,900 per procedure performed to date. That is not a valuation or a price per robot; it only shows the size of the bet against the usage that exists.

The U.S. label is narrow. CMR received FDA clearance in 2025 for Versius Plus, its second-generation robot, but only for gallbladder procedures, and plans to seek more soft-tissue indications, per MedTech Dive. That is a thin indication for a platform Stryker will now sell exclusively, and it means every U.S. procedure Stryker's reps can book on day one is a gallbladder operation. The release itself says nothing about the label.

Who is on each side

Stryker describes itself as a medical technology company spanning MedSurg, Neurotechnology and Orthopaedics, and says it reaches more than 150 million patients a year. CMR is a private company founded in 2014 with an international shareholder base. Its pitch, in Stryker's words, is a modular architecture built for flexibility across procedures, surgeon access and sites of care, designed to fit within existing operating room workflows.

Pierce said Stryker picked CMR for "the opportunity to help healthcare providers grow robotic-assisted surgery adoption across a broad range of procedures", per MedTech Dive's excerpt. A broad range of procedures is the pitch; one cleared procedure is the current U.S. label.

Where it fits against da Vinci, Medtronic and J&J

The da Vinci system is the market leader, and the article gives no installed-base or share figures for it. Johnson & Johnson and Medtronic have also won FDA authorization for their own soft-tissue robots, MedTech Dive reports.

Marcus said "we don't think Stryker/CMR will be effective at displacing da Vinci in the [U.S.] any time soon" and that the deal is "likely to hurt Medtronic and J&J more at the margins". He suggested Stryker may first sell Versius into lower-cost settings such as ambulatory surgery centers; Stryker's own release names hospitals and ASCs as target settings. Versius's modular design lets it move between operating rooms, per the same article.

Wise framed the timing differently: "it feels like a now or never moment for Stryker to make the decision." He also said "the door always seemed open" for Stryker to enter the market, and that Mako experience plus a large hospital operating room equipment business made soft-tissue robotics an expected next step. Stryker's robotics base is its Mako orthopaedic system, which MedTech Dive says reported record installations in the first quarter. Mako is an orthopaedic system, and Stryker's release itself calls this alliance its entry into soft-tissue robotics.

What would change the read

Three things would move this from an option to a position: the closing of the investment after regulatory approvals, a second Versius Plus indication from the FDA beyond gallbladder, and the first U.S. installed-base count under Stryker's sales agency. The structure echoes how Apple's Huxe arrangement sat in a filing with a non-exclusive licence and no price, and how Cloudflare's Deno purchase named no price either. In all three, the missing figure is the one a reader would most want.

The release does not say when Stryker must decide. Until it does, the option is a right with no expiry that anyone outside the two companies can see.